Department of Cardiology, General Hospital of Beijing Military Command, Beijing 100125, P.R. China.
Mol Med Rep. 2013 Apr;7(4):1310-8. doi: 10.3892/mmr.2013.1301. Epub 2013 Jan 30.
Numerous studies have indicated that the human endothelial nitric oxide synthase (eNOS) gene Glu298Asp polymorphism is associated with coronary heart disease (CHD) susceptibility, however, their conclusions are inconsistent. The present meta‑analysis aimed to evaluate the precise result by searching the PubMed database and using 39 case‑control studies comprising 7489 cases and 7051 controls.Each study tested the association between the eNOS Glu298Asp polymorphism and CHD. A meta‑analysis was then conducted using the Comprehensive Meta Analysis 2.2 software to calculate the pooled odds ratios (ORs) of five genetic models with 95% confidence intervals (CIs). Publication bias was also explored. The meta‑analysis showed a significant association between the eNOS Glu298Asp polymorphism and CHD susceptibility for all the genetic models [Asp vs. Glu, OR 1.26, 95% CI 1.14‑1.40, P<0.001; Asp/Asp vs. Glu/Glu, OR 1.58, 95% CI 1.23‑2.02, P<0.001; Glu/Asp vs. Glu/Glu, OR 1.12, 95% CI 1.03‑1.22, P=0.001; (Glu/Asp+Asp/Asp) vs. Glu/Glu, OR 1.17, 95% CI 1.07‑1.27, P<0.001; Asp/Asp vs. (Glu/Glu+Glu/Asp), OR 1.59, 95% CI 1.25‑2.03, P<0.001]. Subgroup and sensitivity analyses indicated that the result was robust. A weak publication bias was detected. The results indicated that the eNOS Glu298Asp polymorphism is a risk factor for developing CHD, particularly in the Asian population.
大量研究表明，人类内皮型一氧化氮合酶（eNOS）基因Glu298Asp 多态性与冠心病（CHD）易感性相关，但结论并不一致。本研究旨在通过检索 PubMed 数据库，纳入 39 项包含 7489 例病例和 7051 例对照的病例对照研究，应用综合 Meta 分析 2.2 软件计算 5 种遗传模型的汇总比值比（OR）及其 95%置信区间（CI），以评估该多态性与 CHD 易感性之间的确切关联。同时还探讨了发表偏倚。Meta 分析结果显示，所有遗传模型均显示 eNOS Glu298Asp 多态性与 CHD 易感性显著相关[Asp 等位基因对比 Glu 等位基因，OR=1.26，95%CI：1.14-1.40，P<0.001；Asp/Asp 等位基因对比 Glu/Glu 等位基因，OR=1.58，95%CI：1.23-2.02，P<0.001；Glu/Asp 等位基因对比 Glu/Glu 等位基因，OR=1.12，95%CI：1.03-1.22，P=0.001；（Glu/Asp+Asp/Asp）等位基因对比 Glu/Glu 等位基因，OR=1.17，95%CI：1.07-1.27，P<0.001；Asp/Asp 等位基因对比（Glu/Glu+Glu/Asp）等位基因，OR=1.59，95%CI：1.25-2.03，P<0.001]。亚组和敏感性分析表明结果稳健。检测到存在微弱的发表偏倚。结果表明，eNOS Glu298Asp 多态性是 CHD 的危险因素，尤其是在亚洲人群中。
